Modality
mAb
MOA
KRASG12Di
Target
PD-1
Pathway
Apoptosis
DravetObesityProstate Ca
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
Dec 2018
→ Jul 2028
Phase 1Current
NCT07785506
2,636 pts·Prostate Ca
2018-12→2028-07·Active
NCT07188439
1,796 pts·Obesity
2025-05→TBD·Active
4,432 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-102.3y awayInterim· Prostate Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Active
P1
Active
Catalysts
Interim
2028-07-10 · 2.3y away
Prostate Ca
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07785506 | Phase 1 | Prostate Ca | Active | 2636 | UPCR |
| NCT07188439 | Phase 1 | Obesity | Active | 1796 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |